Premium
Effects of potentially functional polymorphisms in suppressor of cytokine signaling 3 ( SOCS 3 ) on the risk of head and neck squamous cancer
Author(s) -
Hang Dong,
Yin Yin,
Wang Lihua,
Yuan Hua,
Du Jiangbo,
Zhu Meng,
Dai Juncheng,
Chen Ning,
Hu Zhibin,
Shen Hongbing,
Ma Hongxia
Publication year - 2017
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/jop.12539
Subject(s) - head and neck squamous cell carcinoma , odds ratio , oncology , carcinogenesis , medicine , allele , cancer research , bioinformatics , biology , cancer , head and neck cancer , gene , genetics
Background Suppressor of cytokine signaling 3 ( SOCS 3 ) has been identified as an inhibitor of JAK / STAT pathway that plays a significant role in carcinogenesis. SOCS 3 and JAK 2 polymorphisms may influence the gene expression or function, contributing to the disease susceptibility; however, such effect has not been evaluated in head and neck squamous cell carcinoma ( HNSCC ). Methods A case–control study was performed to test the associations of SOCS 3 and JAK 2 polymorphisms with risk of HNSCC in 576 cases and 1552 cancer‐free controls from China. Seven potentially functional polymorphisms predicted by bioinformatics tools were genotyped using Infinium BeadChip platform. The association between genotypes and HNSCC risk was estimated by computing odds ratios ( OR s) and 95% confidence intervals ( CI s) in univariate and multivariate logistic regression models. Results We found that rs2280148 located at 3′‐untranslated region of SOCS 3 was significantly associated with an increased risk of HNSCC (additive model: adjusted OR = 1.21, 95% CI = 1.03–1.43, P = 0.021). Moreover, rs8064821 located in the promoter region of SOCS 3 was linked with a decreased risk of the cancer (additive model: adjusted OR = 0.83, 95% CI = 0.71–0.97, P = 0.022). Combined analysis of these variants by the number of risk alleles showed a significant locus–dosage effect on the risk of HNSCC ( P trend = 0.006). Conclusions We provided the first evidence that SOCS 3 polymorphisms may influence the risk of HNSCC , which could be applied as novel biomarkers to identify individuals at high risk of the disease.